Switch theme
Sign up to access all valuation multiples
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
2004
19
LTM Revenue $106M
LTM EBITDA $68.7M
$991M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neuren Pharma has a last 12-month revenue (LTM) of $106M and a last 12-month EBITDA of $68.7M.
In the most recent fiscal year, Neuren Pharma achieved revenue of $137M and an EBITDA of $113M.
Neuren Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neuren Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $106M | XXX | $137M | XXX | XXX | XXX |
| Gross Profit | $106M | XXX | $137M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $68.7M | XXX | $113M | XXX | XXX | XXX |
| EBITDA Margin | 65% | XXX | 82% | XXX | XXX | XXX |
| EBIT | $70.7M | XXX | $113M | XXX | XXX | XXX |
| EBIT Margin | 67% | XXX | 82% | XXX | XXX | XXX |
| Net Profit | $59.3M | XXX | $91.2M | XXX | XXX | XXX |
| Net Margin | 56% | XXX | 67% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Neuren Pharma's stock price is AUD 14 (or $9).
Neuren Pharma has current market cap of AUD 1.8B (or $1.1B), and EV of AUD 1.5B (or $991M).
See Neuren Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $991M | $1.1B | XXX | XXX | XXX | XXX | $0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Neuren Pharma has market cap of $1.1B and EV of $991M.
Neuren Pharma's trades at 7.2x EV/Revenue multiple, and 8.8x EV/EBITDA.
Equity research analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neuren Pharma has a P/E ratio of 19.1x.
See valuation multiples for Neuren Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $991M | XXX | $991M | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBITDA | 14.4x | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBIT | 14.0x | XXX | 8.8x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.1x | XXX | 12.4x | XXX | XXX | XXX |
| EV/FCF | 38.7x | XXX | -136.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeuren Pharma's last 12 month revenue growth is -38%
Neuren Pharma's revenue per employee in the last FY averaged $7.2M, while opex per employee averaged $1.3M for the same period.
Neuren Pharma's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neuren Pharma's rule of X is -31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neuren Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -38% | XXX | -19% | XXX | XXX | XXX |
| EBITDA Margin | 65% | XXX | 82% | XXX | XXX | XXX |
| EBITDA Growth | -69% | XXX | -76% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $7.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuren Pharma acquired XXX companies to date.
Last acquisition by Neuren Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Neuren Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Neuren Pharma founded? | Neuren Pharma was founded in 2004. |
| Where is Neuren Pharma headquartered? | Neuren Pharma is headquartered in Australia. |
| How many employees does Neuren Pharma have? | As of today, Neuren Pharma has 19 employees. |
| Who is the CEO of Neuren Pharma? | Neuren Pharma's CEO is Mr. Jonathan Pilcher. |
| Is Neuren Pharma publicy listed? | Yes, Neuren Pharma is a public company listed on ASX. |
| What is the stock symbol of Neuren Pharma? | Neuren Pharma trades under NEU ticker. |
| When did Neuren Pharma go public? | Neuren Pharma went public in 2005. |
| Who are competitors of Neuren Pharma? | Similar companies to Neuren Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Neuren Pharma? | Neuren Pharma's current market cap is $1.1B |
| What is the current revenue of Neuren Pharma? | Neuren Pharma's last 12 months revenue is $106M. |
| What is the current revenue growth of Neuren Pharma? | Neuren Pharma revenue growth (NTM/LTM) is -38%. |
| What is the current EV/Revenue multiple of Neuren Pharma? | Current revenue multiple of Neuren Pharma is 9.4x. |
| Is Neuren Pharma profitable? | Yes, Neuren Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neuren Pharma? | Neuren Pharma's last 12 months EBITDA is $68.7M. |
| What is Neuren Pharma's EBITDA margin? | Neuren Pharma's last 12 months EBITDA margin is 65%. |
| What is the current EV/EBITDA multiple of Neuren Pharma? | Current EBITDA multiple of Neuren Pharma is 14.4x. |
| What is the current FCF of Neuren Pharma? | Neuren Pharma's last 12 months FCF is $25.6M. |
| What is Neuren Pharma's FCF margin? | Neuren Pharma's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Neuren Pharma? | Current FCF multiple of Neuren Pharma is 38.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
